1Arena E,Ferrero S.Surgical treatment of liver metastases from breast cancer[J].Minerva Chir,2004,59(1):7.
2Vlastos G,Smith DL,Singletary SE,et al.Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases[J].Ann Surgical Oncology,2004,11(9):869.
3Winer EP,Berry DA,Woolf S,et al.Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer[J].Journal of Clinical Oncology,2004,22(11):2061.
4Perez EA,Hillman DW,Mailliard JA,et al.Randomized phase Ⅱ study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline,a taxane,or both[J].Journal of Clinical Oncology,2004,22(14):2849.
5Frontini L,Lissoni P,Vaghi M,et al.Enhancement of the efficacy of weekly low-dose taxotere by the long acting anti-prolactinemic drug cabergoline in pretreated metastatic breast cancer[J].Anticancer Res,2004,24(6):4223.
6Reyno L.Phase Ⅲ study of N,N-diethyl-2-[4-(phenyl methyl) phenoxy] ethanamine(BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer[J].Journal of Clinical Oncology,2004,22(2):269.
7Mavroudis D,Malamos N,Polyzos A,et al.Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer:a multicenter phase Ⅱ study[J].Oncology,2004,67(3～4):250.
8Miles D,Vukelja S.Survival benefit with capecitabine/docetaxel versus docetaxel alone:analysis of therapy in a randomized phase Ⅲ trial[J].Clinical Breast Cancer,2004,5(4):273.
9Alba E,Martin M,Ramos M,et al.Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer[J].Journal of Clinical Oncology,2004,22(13):2587.
10Paridaens R,Van Aelst F,Georgoulias V,et al.A randomized phase Ⅱ study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer[J].Ann Oncology,2003,14(3):433.
5Gofuku J,Yayoi E,Ikeda N,et al.Long-term survivors with liver metastasis from breast cancer who were received intra-arterial chemotherapy.Gan to Kagaku Ryoho,2004,31(11):1828-1831.
6Vlastos G,Smith D L,Singletary S E,et al.Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases.Ann Surgical Oncology,2004,11(9):869-874.
7Plouzek C A,Cilino H P,Clake R,et al.Inhibition of P-glycoprotein activity and reversal of mutidrug resistance in vitro by rose mary extract.Eur J Cancer,1999,35(10):1541.
8J. A. O’Shaughnessy,J. Blum,V. Moiseyenko,S. E. Jones,D. Miles,D. Bell,R. Rosso,L. Mauriac,B. Osterwalder,H.-U. Burger,S. Laws. Randomized, open-label, phase II trial of oral capecitabine (Xeloda?) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer[J] 2001,Annals of Oncology(9):1247～1254
9R. E. Coleman,A. Howell,S. P. H. Eggleton,S. J. Maling,D. W. Miles. Phase II study of docetaxel in patients with liver metastases from breast cancer[J] 2000,Annals of Oncology(5):541～546
10Sawada N, Ishikowa T, Fukase Y, et al. Induction of thymi- dine phosphorylase activity and enhancement of capecitabine ef- ficacy by taxol/taxotere in human cancer xenografts [ J] . Clin Cancer Res, 1998, 4 (4) : 1013 -1019.
